Stocks & Investing
Thu, May 16, 2024
[ 12:00 AM ] - WOPRAI
Thu, April 11, 2024
[ 12:00 AM ] - WOPRAI
Tue, March 26, 2024
[ 12:00 AM ] - WOPRAI
Fri, March 15, 2024
[ 12:00 AM ] - WOPRAI
Tue, November 21, 2023
[ 12:00 AM ] - WOPRAI
Thu, August 10, 2023
[ 12:00 AM ] - WOPRAI
Mon, June 26, 2023
[ 12:00 AM ] - WOPRAI
Tue, May 16, 2023
[ 12:00 AM ] - WOPRAI
Wed, March 29, 2023
[ 12:00 AM ] - WOPRAI
Wed, November 16, 2022
[ 12:00 AM ] - WOPRAI
Fri, June 3, 2022
[ 12:00 AM ] - WOPRAI
Tue, May 18, 2021
[ 12:00 AM ] - WOPRAI
Justin Zelin Initiated (TCRX) at Strong Buy and Held Target at $12 on, May 16th, 2024
Justin Zelin of BTIG, Initiated "TScan Therapeutics, Inc." (TCRX) at Strong Buy and Held Target at $12 on, May 16th, 2024.
Justin has made no other calls on TCRX in the last 4 months.
There are 4 other peers that have a rating on TCRX. Out of the 4 peers that are also analyzing TCRX, 0 agree with Justin's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Justin
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $15 on, Tuesday, May 14th, 2024
- Gil Blum of "Needham" Reiterated at Strong Buy and Held Target at $11 on, Monday, May 13th, 2024
- David Nierengarten of "Wedbush" Reiterated at Buy and Held Target at $10 on, Tuesday, April 23rd, 2024
- Peter Lawson of "Barclays" Maintained at Buy with Increased Target to $9 on, Thursday, March 7th, 2024
